Pablo R Moya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/674139/publications.pdf

Version: 2024-02-01

39 papers 1,441 citations

430874 18 h-index 330143 37 g-index

44 all docs

44 docs citations

44 times ranked 2120 citing authors

#	Article	lF	CITATIONS
1	How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology, 2008, 55, 932-960.	4.1	199
2	A Haplotype Containing Quantitative Trait Loci for SLC1A1 Gene Expression and Its Association With Obsessive-Compulsive Disorder. Archives of General Psychiatry, 2009, 66, 408.	12.3	131
3	A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Human Molecular Genetics, 2007, 17, 717-723.	2.9	119
4	Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1054-1061.	2. 5	105
5	Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. Cellular and Molecular Life Sciences, 2021, 78, 4615-4637.	5.4	85
6	Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120435.	4.0	84
7	Metaâ€analysis of association between obsessiveâ€compulsive disorder and the 3′ region of neuronal glutamate transporter gene <i>SLC1A1</i> . American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 367-379.	1.7	83
8	Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. Current Opinion in Pharmacology, 2011, 11, 3-10.	3 . 5	82
9	Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors. British Journal of Pharmacology, 2002, 136, 510-519.	5.4	69
10	miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. International Journal of Neuropsychopharmacology, 2013, 16, 621-629.	2.1	51
11	Lentivirally mediated GSK- $3\hat{l}^2$ silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. International Journal of Neuropsychopharmacology, 2011, 14, 711-717.	2.1	44
12	Common and rare alleles of the serotonin transporter gene, <i>SLC6A4</i> , associated with Tourette's disorder. Movement Disorders, 2013, 28, 1263-1270.	3.9	44
13	Increased gene expression of diacylglycerol kinase eta in bipolar disorder. International Journal of Neuropsychopharmacology, 2010, 13, 1127-1128.	2.1	38
14	Rare missense neuronal cadherin gene (CDH2) variants in specific obsessive-compulsive disorder and Tourette disorder phenotypes. European Journal of Human Genetics, 2013, 21, 850-854.	2.8	38
15	Pharmacological Identification of P2X1, P2X4 and P2X7 Nucleotide Receptors in the Smooth Muscles of Human Umbilical Cord and Chorionic Blood Vessels. Placenta, 2003, 24, 17-26.	1.5	31
16	Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacology, $2011, 11, 3$.	0.4	28
17	Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. Neuropsychopharmacology, 2019, 44, 1163-1173.	5 . 4	27
18	<i>N</i> , <i>N</i> , <i>N</i> ,6€dimethylâ€thioamphetamine and methylâ€thioamphetamine, two nonâ€neurotoxic substrates of 5â€HT transporters, have scant <i>in vitro</i> efficacy for the induction of transporterâ€mediated 5â€HT release and currents. Journal of Neurochemistry, 2008, 105, 1770-1780.	3.9	19

#	Article	IF	CITATIONS
19	A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study. Molecular Psychiatry, 2011, 16, 584-585.	7.9	19
20	Neonatal exposure to oestradiol increases dopaminergic transmission in nucleus accumbens and morphineâ€induced conditioned place preference in adult female rats. Journal of Neuroendocrinology, 2018, 30, e12574.	2.6	19
21	Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans. Pharmacogenomics Journal, 2013, 13, 551-557.	2.0	14
22	Programming of Dopaminergic Neurons by Neonatal Sex Hormone Exposure: Effects on Dopamine Content and Tyrosine Hydroxylase Expression in Adult Male Rats. Neural Plasticity, 2016, 2016, 1-11.	2.2	14
23	4â€Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects <i>In Vivo</i> . Basic and Clinical Pharmacology and Toxicology, 2012, 111, 371-379.	2.5	12
24	In a Model of Batten Disease, Palmitoyl Protein Thioesterase-1 Deficiency Is Associated with Brown Adipose Tissue and Thermoregulation Abnormalities. PLoS ONE, 2012, 7, e48733.	2.5	12
25	Ketamine-Treatment During Late Adolescence Impairs Inhibitory Synaptic Transmission in the Prefrontal Cortex and Working Memory in Adult Rats. Frontiers in Cellular Neuroscience, 2019, 13, 372.	3.7	12
26	The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder. Frontiers in Pharmacology, 2019, 10, 1362.	3. 5	11
27	Altered Grooming Syntax and Amphetamine-Induced Dopamine Release in EAAT3 Overexpressing Mice. Frontiers in Cellular Neuroscience, 2021, 15, 661478.	3.7	8
28	Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice. Biological Research, 2017, 50, 29.	3 . 4	7
29	Amphetamine treatment affects the extraâ€hypothalamic vasopressinergic system in a sex―and nucleusâ€dependent manner. Journal of Neuroendocrinology, 2017, 29, .	2.6	6
30	3D similarities between the binding sites of monoaminergic target proteins. PLoS ONE, 2018, 13, e0200637.	2.5	5
31	Genetic contributions to obsessive–compulsive disorder (OCD) and OCD-related disorders. , 2012, , 121-133.		4
32	Improving Amphetamine Therapeutic Selectivity: <i>N,N</i> â€dimethylâ€ <scp>MTA</scp> has Dopaminergic Effects and does not Produce Aortic Contraction. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 395-399.	2.5	4
33	Mini-revisión: Variantes genéticas del transportador de serotonina en trastornos neuropsiquiátricos. Revista Chilena De Neuro-Psiquiatria, 2014, 52, 115-122.	0.1	3
34	Connecting Synaptic Activity with Plasticity-Related Gene Expression: From Molecular Mechanisms to Neurological Disorders. Neural Plasticity, 2016, 2016, 1-3.	2.2	3
35	Lack of Association between the IL6R Gene Asp358Ala Variant (rs2228145), IL-6 Plasma Levels, and Treatment Resistance in Chilean Schizophrenic Patients Treated with Clozapine. Schizophrenia Research and Treatment, 2019, 2019, 1-5.	1.5	3
36	Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness. International Journal of Neuropsychopharmacology, 2022, 25, 701-708.	2.1	2

#	Article	IF	CITATIONS
37	Dennis Luke Murphy, M.D. (1936–2017). Genes, Brain and Behavior, 2018, 17, e12455.	2.2	1
38	Esquizofrenia resistente: Definiciones e Implicancias del concepto de Esquizofrenia Resistente a tratamiento. Revista Chilena De Neuro-Psiquiatria, 2019, 57, 394-404.	0.1	1
39	ABCB1 and ABCC2 gene polymorphisms and response to anticonvulsant therapy in patients with idiopathic epilepsy from the neurology clinics at Van Buren Hospital. Journal of the Neurological Sciences, 2017, 381, 684-685.	0.6	0